1THOMPSON C A.FDA approves kallikrein inhibitor to treat he-reditary angioedema[].American Journal of Health System Pharmacy.2010
2.International nonproprietary names for pharmaceutical substances(INN):List 55[].WHO Drug Inf.2006
3REVILL P,MEALY N.Ecallantide:plasma kallikrein inhibitortreatment of hereditary angioedema[].Drugs of the Future.2007
4LEVY J H,FREIBERGER D J,ROBACK J.Hereditary angioe-dema:current and emerging treatment options[].Anesthesia and Analgesia.2010
5LEHMANN A.Ecallantide (DX-88)a plasma kallikrein inhibi-tor for the treatment of hereditary angioedema and the preventionof blood loss in on-pump cardiothoracic surgery[].Expert Opinion on Biological Therapy.2008
6FANKMM,JIANG H.Newtherapies for hereditary angioedema:disease outlook changes dramatically[].Allergy and Clinical Immunology International.2008
7LEHMANN A.Ecallantide (Dyax/Genzyme)[].Current Opinion in Investigational Drugs.2006
8LUMRY W,RITCHIE B,BECK Tet al.Interim results of E-DEMA2 a multicenter open-label repeat dosing study of intra-venous and subcutaneous administration of ecallantide(DX-88)in hereditary angioedema[].Allergy and Clinical Immunology International.2006
9ZURAW B,YASOTHAN U,KIRKPATRICK P.Ecallantide[].Nature Reviews Drug Discovery.2010
10LI HH,LEVY R J,MCNEIL D Let al.Interim open-label re-sults of EDEMA3:A study of subcutaneous ecallaneide in patientswith hereditary angioedema[].Allergy and Clinical Immunology International.2007
